Skip to main content

Table 4 Trials evaluating preoperative anti-angiogenic treatment and RT in STS

From: Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03)

Author Evaluated patients Treatment regimen Tumor site Patients with toxicity (CTCAE) ≥ grade 3 Type of toxicity (CTCAE) ≥ grade 3 Path. response: ≥ 90 % non-viable tissue
Haas 2015 11 Pazopanib/RT Extremity (n = 11) 3/11 Hepatotoxicity 4/10
Canter 2014 8 Sorafenib/RT Extremity (n = 8) 4/8 Skin rash (n = 2), anemia, perirectal abscess, supraventricular tachycardia 3/8
Yoon 2011 20 Bevacizumab/RT Extremity (n = 13) Retro (n = 6) Trunk (n = 1) 4/20 Hepatotoxicity, hypertension 7/20
Lewin 2014 9 Sunitinib/RT Extremity (n = 9) 7/9 Hepatotoxicity, hematotoxicity, hyponatremia, hyperglycemia, skin rash Not reported
Jakob 2015 16 Sunitinib/RT Extremity (n = 5) Retro (n = 10) Trunk (n = 1) 8/16 Hematotoxicity, hand-foot-syndrome 5/16
Sunrase (this trial) 9 Sunitinib/RT Extremity (n = 3) Retro (n = 4) Trunk (n = 2) 5/9 Hematotoxicity 3/9
Sunyach 2014 10 Sunitinib/RT Extremity (n = 10) Only DLT reported Thrombopenia grade 4 (n = 1), no other dose limiting toxicity Not applicable, therapy given for unresectable tumors